FDA

Insurance reimbursement for psychedelic therapy is integral to treatment accessibility.

The convergence of current psychedelics regulatory pathways may bring benefits and new challenges.

Two essays by the student winners of a Penn Carey Law essay competition describe important regulatory issues.

Scholars urge Congress to give FDA more power to regulate dietary supplements.

Scholars analyze FDA’s emergency use authorizations during the COVID-19 pandemic.

Experts recommend measures to improve the regulation of dietary supplements.

Researchers explore the optimal cost-benefit considerations of medical device cybersecurity risks.

Scholar argues that FDA should adopt an evidenced-based approach to regulating drug manufacturers’ speech.

Scholar argues for greater privacy protections of personal medical data collected by wearable health technologies.

Scholar argues that FDA should be the sole regulator of cell-cultured meat.

FDA approves first over-the-counter treatment to combat the opioid overdose epidemic.

Existing patents deter the marketing of more affordable generic drugs that could be used off-label for abortions.